Emory surgical oncologists provide multi-modality evaluation and surgical treatment as part of the Winship Cancer Institute of Emory University, Emory's cross-disciplinary cancer treatment, prevention, and research center and Georgia's first and only NCI Designated Cancer Center. U.S. News & World Report ranks cancer care at Emory University Hospital through Winship in the top 25 cancer programs in the nation. Winship emphasizes applying the latest research as quickly and responsibly as possible to patient care, giving Emory surgical oncologists the opportunity to offer ground-breaking treatment to their patients due to their involvement in progressive bench and clinical research.
Dr. Charles Staley has been chief of the division of surgical oncology since 1995. Known for conducting novel clinical trials in gastrointestinal cancers, Dr. Staley specializes in treating cancers of the esophagus, pancreas, stomach, liver, small bowel, and rectum. He has investigated gene therapy for metastatic colon cancer and radiofrequency ablation with intra-arterial chemotherapy for patients with colorectal liver metastases. Currently, he and his colleagues are exploring methods of using nanotechnology to treat and diagnose pancreatic and breast cancer.
In 2014, Dr. Staley was named Co-PI of the Winship Cancer Institute location of the National Cancer Institute's National Clinical Trials Network (NCTN) with Emory medical oncology chief Dr. Suresh Ramalingam and Emory radiation oncologist Dr. Jonathan Beitler. Effective March 1st, 2014, the NCTN began serving as NCI's primary infrastructure to conduct phase II and III cancer clinical trials, and is expected to enroll over 17,000 patients per year with a variety of cancer types and from diverse backgrounds.
The surgical oncology training program has developed and standardized significantly over the past several years by broadening the scope and measurability of the general surgery resident's learning experience during rotations. The division also offers a breast cancer fellowship officially approved by the Society of Surgical Oncology.